Axogen, Inc. (LON:0HKD)

Market Cap	1.05B
Revenue (ttm)	159.73M
Net Income (ttm)	-1.56M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	67.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61
Average Volume	1,631
Open	30.21
Previous Close	29.93
Day's Range	30.01 - 30.31
52-Week Range	9.29 - 34.23
Beta	0.76
RSI	62.79
Earnings Date	Feb 27, 2026

About Axogen

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• CEO: Michael Dale
• Employees: 452
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKD

Financial Performance

In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.

Financial numbers in USD